Loading...

We've got a brand new version of Simply Wall St! Try it out

Prescient Therapeutics

ASX:PTX
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PTX
ASX
A$17M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The last earnings update was 85 days ago. More info.


Add to Portfolio Compare Print
  • Prescient Therapeutics has significant price volatility in the past 3 months.
PTX Share Price and Events
7 Day Returns
2%
ASX:PTX
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-37.5%
ASX:PTX
50.9%
AU Biotechs
16.3%
AU Market
PTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prescient Therapeutics (PTX) 2% -7.4% 22% -37.5% -46.8% -68.8%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • PTX underperformed the Biotechs industry which returned 50.9% over the past year.
  • PTX underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
PTX
Industry
5yr Volatility vs Market

Value

 Is Prescient Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Prescient Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is A$0.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prescient Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prescient Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:PTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.02
ASX:PTX Share Price ** ASX (2019-11-18) in AUD A$0.05
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prescient Therapeutics.

ASX:PTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PTX Share Price ÷ EPS (both in AUD)

= 0.05 ÷ -0.02

-3.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prescient Therapeutics is loss making, we can't compare its value to the Global Biotechs industry average.
  • Prescient Therapeutics is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Prescient Therapeutics's expected growth come at a high price?
Raw Data
ASX:PTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
34.2%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prescient Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prescient Therapeutics's assets?
Raw Data
ASX:PTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.04
ASX:PTX Share Price * ASX (2019-11-18) in AUD A$0.05
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:PTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PTX Share Price ÷ Book Value per Share (both in AUD)

= 0.05 ÷ 0.04

1.38x

* Primary Listing of Prescient Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prescient Therapeutics is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Prescient Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Prescient Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Prescient Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prescient Therapeutics expected to grow at an attractive rate?
  • Prescient Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Prescient Therapeutics's earnings growth is expected to exceed the Australia market average.
  • Prescient Therapeutics's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:PTX Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:PTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 34.2%
ASX:PTX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 71.9%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:PTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:PTX Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-06-30 93 28 1
2023-06-30 45 -1 1
2022-06-30 2 -28 1
2021-06-30 0 -12 1
2020-06-30 0 -7 1
2019-11-18
ASX:PTX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 2 -4 -4
2019-03-31 1 -3 -3
2018-12-31 1 -3 -3
2018-09-30 1 -2 -3
2018-06-30 1 -2 -3
2018-03-31 1 -3 -3
2017-12-31 1 -3 -3
2017-09-30 1 -3 -3
2017-06-30 1 -3 -3
2017-03-31 1 -3 -2
2016-12-31 1 -2 -2
2016-09-30 1 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Prescient Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Prescient Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:PTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Prescient Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PTX Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-06-30 0.04 0.04 0.04 1.00
2023-06-30 0.00 0.00 0.00 1.00
2022-06-30 -0.04 -0.04 -0.04 1.00
2021-06-30 -0.02 -0.02 -0.02 1.00
2020-06-30 -0.01 -0.01 -0.01 1.00
2019-11-18
ASX:PTX Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.02
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Prescient Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Prescient Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prescient Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Prescient Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prescient Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prescient Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Prescient Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Prescient Therapeutics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Prescient Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prescient Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PTX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1.65 -3.80 1.86 3.68
2019-03-31 1.44 -3.39 1.76 3.19
2018-12-31 1.36 -2.99 1.66 2.70
2018-09-30 1.21 -2.78 1.60 2.38
2018-06-30 0.94 -2.57 1.55 2.06
2018-03-31 1.03 -2.65 1.42 2.27
2017-12-31 1.12 -2.72 1.28 2.48
2017-09-30 1.17 -2.65 1.31 2.46
2017-06-30 1.22 -2.57 1.33 2.43
2017-03-31 1.04 -2.36 1.55 1.82
2016-12-31 0.85 -2.16 1.77 1.21
2016-09-30 0.93 -1.95 1.86 1.00
2016-06-30 1.00 -1.75 1.95 0.80
2016-03-31 0.97 -1.72 1.78 0.91
2015-12-31 0.93 -1.69 1.61 1.02
2015-09-30 0.59 -1.91 1.48 1.01
2015-06-30 0.25 -2.13 1.34 0.99
2015-03-31 0.15 -1.89 1.29 0.69
2014-12-31 0.04 -1.65 1.24 0.40
2014-09-30 0.02 -1.71 1.28 0.20
2014-06-30 0.01 -1.77 1.32
2014-03-31 0.00 -1.48 1.03 0.00
2013-12-31 0.00 -1.19 0.74 0.00
2013-09-30 0.00 0.30 0.59 0.00
2013-06-30 1.79 0.43 0.00
2013-03-31 0.07 1.40 0.71 0.07
2012-12-31 0.13 1.01 0.99 0.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Prescient Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Prescient Therapeutics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Prescient Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Prescient Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prescient Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Prescient Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prescient Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prescient Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prescient Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Prescient Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Prescient Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prescient Therapeutics Company Filings, last reported 4 months ago.

ASX:PTX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 14.32 0.00 9.66
2019-03-31 14.32 0.00 9.66
2018-12-31 7.98 0.00 3.33
2018-09-30 7.98 0.00 3.33
2018-06-30 9.44 0.06 5.51
2018-03-31 9.44 0.06 5.51
2017-12-31 10.67 0.00 6.01
2017-09-30 10.67 0.00 6.01
2017-06-30 11.78 0.00 7.67
2017-03-31 11.78 0.00 7.67
2016-12-31 13.24 0.00 9.45
2016-09-30 13.24 0.00 9.45
2016-06-30 13.01 0.00 9.75
2016-03-31 13.01 0.00 9.75
2015-12-31 5.58 0.00 1.93
2015-09-30 5.58 0.00 1.93
2015-06-30 4.45 0.00 1.04
2015-03-31 4.45 0.00 1.04
2014-12-31 5.21 0.00 2.33
2014-09-30 5.21 0.00 2.33
2014-06-30 5.03 0.00 3.81
2014-03-31 5.03 0.00 3.81
2013-12-31 1.59 0.00 1.51
2013-09-30 1.59 0.00 1.51
2013-06-30 0.00 0.00
2013-03-31 0.00 0.00
2012-12-31 0.00 0.00
  • Prescient Therapeutics has no debt.
  • Prescient Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Prescient Therapeutics has sufficient cash runway for 2.3 years based on current free cash flow.
  • Prescient Therapeutics has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 16.8% each year.
X
Financial health checks
We assess Prescient Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prescient Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Prescient Therapeutics dividends.
If you bought A$2,000 of Prescient Therapeutics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Prescient Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Prescient Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:PTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:PTX Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2024-06-30
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Prescient Therapeutics has not reported any payouts.
  • Unable to verify if Prescient Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Prescient Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Prescient Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Prescient Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prescient Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prescient Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Prescient Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yatomi-Clarke Lee
COMPENSATION A$585,573
TENURE AS CEO 3.8 years
CEO Bio

Mr. Yatomi-Clarke Steven Lee has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Lee has been Director of Prescient Therapeutics Limited since November 28, 2014. He is one of Australia's most experienced biotech capital markets operatives with a successful history of financing many private and public biotech companies over the past decade. Mr. Lee serves as Director of Corporate Finance at Patersons Securities, one of Australia's oldest and largest full service stockbroking firms. He has over 15 years' experience in investment banking across a range of sectors but specialises in healthcare and biotechnology, where he has consistently been one of the most prolific bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies. Mr. Lee is also a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy. Mr. Lee holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology and a Bachelor of Commerce majoring in economics.

CEO Compensation
  • Yatomi-Clarke's compensation has increased whilst company is loss making.
  • Yatomi-Clarke's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Prescient Therapeutics management team in years:

4.5
Average Tenure
64
Average Age
  • The tenure for the Prescient Therapeutics management team is about average.
Management Team

Yatomi-Clarke Lee

TITLE
MD, CEO & Director
COMPENSATION
A$586K
TENURE
3.8 yrs

Said Sebti

TITLE
Chief Scientific Officer
COMPENSATION
A$169K
TENURE
4.5 yrs

Terrence Chew

TITLE
Chief Medical Officer
COMPENSATION
A$165K
AGE
72
TENURE
4.6 yrs

Melanie Jaye Leydin

TITLE
Company Secretary
COMPENSATION
A$102K
AGE
46
TENURE
4.8 yrs

Claudia Gregorio-King

TITLE
Vice President of Operations

Jim Winkler

TITLE
Head of Business Development
AGE
64
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure of the Prescient Therapeutics board of directors in years:

5
Average Tenure
  • The tenure for the Prescient Therapeutics board of directors is about average.
Board of Directors

Steve Engle

TITLE
Non-Executive Chairman
COMPENSATION
A$83K
AGE
64
TENURE
5 yrs

Yatomi-Clarke Lee

TITLE
MD, CEO & Director
COMPENSATION
A$586K
TENURE
5 yrs

Rodney Sinclair

TITLE
Chairman of Clinical Advisory Board
TENURE
8.4 yrs

James Campbell

TITLE
Non-Executive Director
COMPENSATION
A$54K
TENURE
5 yrs

Reinhard Dummer

TITLE
Member of Clinical Advisory Board
TENURE
8.4 yrs

Paul Hopper

TITLE
Non-Executive Director
COMPENSATION
A$54K
AGE
63
TENURE
4.9 yrs

Joshua Douglas

TITLE
Member of Scientific Advisory Board
TENURE
5.2 yrs

Farhad Ravandi

TITLE
Member of Scientific Advisory Board
TENURE
4 yrs

Jeffrey Lancet

TITLE
Member of Scientific Advisory Board
TENURE
4 yrs

Thomas Prebet

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
05. Nov 19 Sell UBS Asset Management Company 12. Sep 19 01. Nov 19 -2,570,787 A$0.06 A$-138,658
11. Jun 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 09. May 19 06. Jun 19 -8,314,728 A$0.05 A$-350,696
11. Jun 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 16. May 19 30. May 19 114,728 A$0.05 A$5,206
12. Jun 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 07. Jun 19 07. Jun 19 -7,000,000 A$0.04 A$-314,995
12. Jun 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 07. Jun 19 07. Jun 19 32,500 A$0.04 A$1,451
14. Jun 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 11. Jun 19 11. Jun 19 -7,000,000 A$0.04 A$-300,994
10. Jun 19 Buy UBS Asset Management Company 04. Apr 19 06. Jun 19 21,622,046 A$0.05 A$937,790
08. May 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 01. Apr 19 09. Apr 19 11,093,843 A$0.05 A$553,664
09. Apr 19 Buy Chris Retzos Individual 28. Jun 17 28. Mar 19 4,211,696 A$0.06 A$262,604
09. Apr 19 Sell Chris Retzos Individual 10. Apr 18 28. Nov 18 -2,475,000 A$0.14 A$-336,870
09. Apr 19 Buy Chris Retzos Individual 10. Apr 18 12. Mar 19 2,286,989 A$0.14 A$200,087
03. Apr 19 Sell Regal Funds Management Pty Limited Company 11. Dec 18 14. Mar 19 -1,890,128 A$0.07 A$-113,302
26. Mar 19 Buy James Campbell Individual 26. Mar 19 26. Mar 19 178,125 A$0.06 A$9,968
12. Dec 18 Sell Regal Funds Management Pty Limited Company 13. Aug 18 10. Dec 18 -2,321,532 A$0.10 A$-207,166
X
Management checks
We assess Prescient Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prescient Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did You Manage To Avoid Prescient Therapeutics's (ASX:PTX) Painful 67% Share Price Drop?

Zooming in on an example, the Prescient Therapeutics Limited (ASX:PTX) share price dropped 67% in the last half decade. … It seems likely some shareholders believe that Prescient Therapeutics has the funding to invent a new product before too long. … Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround.

Simply Wall St -

Does Prescient Therapeutics Limited's (ASX:PTX) CEO Pay Matter?

View our latest analysis for Prescient Therapeutics How Does Yatomi-Clarke Lee's Compensation Compare With Similar Sized Companies? … Given the total loss of 54% over three years, many shareholders in Prescient Therapeutics Limited are probably rather dissatisfied, to say the least. … We compared the total CEO remuneration paid by Prescient Therapeutics Limited, and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

Imagine Owning Prescient Therapeutics (ASX:PTX) And Trying To Stomach The 78% Share Price Drop

Spare a thought for those who held Prescient Therapeutics Limited (ASX:PTX) for five whole years - as the share price tanked 78%. … It seems likely some shareholders believe that Prescient Therapeutics has the funding to invent a new product before too long. … We'd venture that shareholders are concerned about the need for more capital, because the share price has dropped 26% per year, over 5 years.

Simply Wall St -

Is Prescient Therapeutics Limited (ASX:PTX) Overpaying Its CEO?

Yatomi-Clarke Lee has been the CEO of Prescient Therapeutics Limited (ASX:PTX) since 2016. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Yatomi-Clarke Lee's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What Kind Of Investor Owns Most Of Prescient Therapeutics Limited (ASX:PTX)?

Every investor in Prescient Therapeutics Limited (ASX:PTX) should be aware of the most powerful shareholder groups. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of AU$15m, Prescient Therapeutics is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Is Prescient Therapeutics Limited (ASX:PTX) On The Right Side Of Disruption?

Healthcare analysts are forecasting for the entire industry, negative growth in the upcoming year , and an overall negative growth rate in the next couple of years. … See our latest analysis for Prescient Therapeutics What’s the catalyst for Prescient Therapeutics's sector growth? … This lack of growth means Prescient Therapeutics may be trading cheaper than its peers.

Simply Wall St -

Should You Be Concerned About Prescient Therapeutics Limited's (ASX:PTX) Shareholders?

When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … This level of insider ownership has been found to have a negative impact on companies with consistently low PE ratios (underperformers), while it has been positive in the case of high PE ratio firms (outperformers). … Private Company Ownership Another group of owners that a potential investor in PTX should consider are private companies, with a stake of 11.71%.

Simply Wall St -

Is Prescient Therapeutics Limited (ASX:PTX) As Financially Strong As Its Balance Sheet Indicates?

Zero-debt allows substantial financial flexibility, especially for small-cap companies like Prescient Therapeutics Limited (ASX:PTX), as the company does not have to adhere to strict debt covenants. … View our latest analysis for Prescient Therapeutics Is financial flexibility worth the lower cost of capital? … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Was Prescient Therapeutics Limited's (ASX:PTX) EPS Decline A Part Of Broader Industry Downturn?

Check out our latest analysis for Prescient Therapeutics Was PTX's recent earnings decline indicative of a tough track record? … I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … For Prescient Therapeutics, the latest twelve-month earnings -A$2.6M, which, against the previous year's level, has become more negative.

Simply Wall St -

What Kind Of Risk And Return Should You Expect For Prescient Therapeutics Limited (ASX:PTX)?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … PTX's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Company Info

Description

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company’s lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.

Details
Name: Prescient Therapeutics Limited
PTX
Exchange: ASX
Founded:
A$17,347,467
394,260,627
Website: http://ptxtherapeutics.com
Address: Prescient Therapeutics Limited
100 Albert Road,
Level 4,
South Melbourne,
Victoria, 3205,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PTX Ordinary Shares Australian Securities Exchange AU AUD 02. Jan 1992
OTCPK PSTT.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB PTU Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
CHIA PTX Ordinary Shares Chi-X Australia AU AUD 02. Jan 1992
CHIA RAN NPV Chi-X Australia AU AUD 18. Nov 2019
Number of employees
Current staff
Staff numbers
0
Prescient Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:35
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/09/13
Last earnings filing: 2019/08/25
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.